Aurobindo Pharma FY23 consolidated net profit down 27.2pc to RS 1,927.7 cr

Hyderabad, May 28 Aurobindo Pharma’ s consolidated net profit ( after share of profit/loss of JV and before minority interest) declined 27.2 percent to Rs. 1,927.7 crore for the year ended March 31, 2023 against Rs 2,647.1 crore percent in the previous year even as consolidated gross sales (incl service income) increased to Rs 24,855 crore in FY23 from Rs 23,455 crore inFY22.
The consolidated net profit for the fourth quarter in FY23 down 12.2 percent to Rs 505.9 crore against Rs 576.1 crore in the same quarter in FY22, the Hyderabad based pharma company saidin a release here on Saturday.
Consolidated revenue from operations for the quarter stood at Rs 6,473 crore in FY23 against Rs5,809 crore in Q4FY22, registering 11.4 percent growth.
Commenting on the Company’s performance, Pharma Company Vice Chairman and Managing Director Mr. K. Nithyananda Reddy, said, “We saw decent performance in the current quarter,on the back of stable demand and pricing environment across our portfolio and geographies. Were main committed to executing our growth strategies, continuing new launches, and focusing on operational efficiencies.”
As on March 31, 2023, on a cumulative basis, the company has filed 774 ANDAs with USFDA and received final approval for 565 ANDAs and 34 tentative approvals .
The company has launched 10 products during the quarter including 4 Injectable products.